Document:

<PAGE>
                                                                   EXHIBIT 10.25

[MEMORY PHARMACEUTICALS CORP. LOGO]
MEMORY PHARMACEUTICALS CORP.                          Tony Scullion
100 Philips Parkway                                   Chief Executive Officer
Montvale, New Jersey 07645
Phone: (201) 802-7102
Fax: (201) 802-7190
www.memorypharma.com

December 16, 2003

Mr. Dennis Keane
50 Constant Avenue
Yonkers, NY 10701

Dear Dennis:

      We are pleased to inform you that both the Board of Directors and
management team of Memory Pharmaceuticals Corp. (the "Company") are impressed
with your experience and accomplishments, and would like to extend an offer to
you to join our Company as Chief Financial Officer. We look forward to you
joining our team, and are confident that you will contribute significantly to
the value of our organization. We are therefore pleased to provide you with the
terms of your anticipated employment by the Company.

      1. Position. In your position of Chief Financial Officer you will
initially report to the Company's Chief Executive Officer, based out of the
Company's offices currently located in Montvale, New Jersey. As Chief Financial
Officer, you will be part of the senior management team (comprising the senior
executives of the Company), and your responsibilities shall include, but not be
limited to, managing and directing the financial affairs of the Company. In
addition to performing duties and responsibilities associated with the position
of Chief Financial Officer, from time to time the Company may assign you other
duties and responsibilities and/or may assign you to a different location within
fifty (50) miles of the Company's principal office in Montvale, New Jersey.

      As a full-time employee of the Company, you will be expected to devote
your full business time and energies to the business and affairs of the Company.
Your performance will be reviewed formally after six months of employment and
annually thereafter at the end of each calendar year.

      2. Starting Date/Nature of Relationship. It is expected that your
employment will start on January 6, 2004 (the "Start Date"). No provision of
this letter shall be construed to create an express or implied employment
contract for a specific period of time. Either you or the Company may terminate
the employment relationship at any time and for any reason.

      3. Compensation.

         (a)  Your initial salary will be at the bi-weekly rate of $8,269.23
      (annualized at $215,000 per year).

         (b)  You will receive non-qualified stock options to purchase, at fair
      market value to be determined by the Company's Board of Directors
      (currently $0.90 per share), 300,000 Shares of Common Stock of Memory
      Pharmaceuticals Corp., which shall vest in quarterly increments over a
      period of four (4) years as described in the Stock Option Agreement, which
      you and the Company will enter into on or before the Start Date.
<PAGE>
         (c)  You will be eligible to receive annual bonus payments dependent on
      the performance of the Company and your individual performance, subject to
      the discretion of the Board of Directors. Your target bonus will be equal
      to twenty-five percent (25%) of your base salary, assuming the achievement
      of such Company and individual performance objectives.

         (d)  Upon termination for any reason, the Company shall pay you within
      two weeks of such termination, your current base salary earned through the
      termination date, plus accrued vacation, if any, and other benefits or
      payments, if any, to which you are entitled. In the event you are
      terminated by the Company, without "Cause" (as hereinafter defined), then
      the Company shall continue to pay you your bi-weekly rate in effect at the
      time of termination and provide and pay the Company's portion of your
      medical insurance for a period of six months. Further, for the period
      commencing seven months following such termination and ending twelve
      months after such termination, the Company shall continue to pay you your
      bi-weekly rate in effect at the time of termination and provide and pay
      the Company's portion of your medical insurance, except that such
      severance payments made to you during this period shall be reduced by all
      1099 and W-2 income earned or received by you during such period,
      including income earned or received from consulting services or temporary
      employment. The Company shall reconcile such payments with you quarterly,
      and any additional payments owed to you by the Company, and any payments
      owed to the Company by you, shall be paid respectively within two weeks
      following such reconciliation period. In addition, upon termination of
      your employment without "Cause," you will be entitled to accelerated
      vesting of your stock options as if your employment was terminated one
      year after your actual termination date. The Company shall not be
      obligated to continue any such payments to you or accelerate vesting of
      your stock options under this paragraph 3(e) in the event you materially
      breach the terms under the Confidentiality Agreement attached hereto.
      Notwithstanding any termination of your employment for any reason (with or
      without Cause), you shall continue to be bound by the provisions of the
      Confidentiality Agreement.

         (e)  For the purposes of this Section 3, "Cause" shall include (i) your
      conviction of a felony, either in connection with the performance of your
      obligations to the Company or otherwise, which adversely affects your
      ability to perform such obligations or materially adversely affects the
      business activities, reputation, goodwill or image of the Company, (ii)
      your willful disloyalty, deliberate dishonesty, breach of fiduciary duty,
      (iii) your breach of the terms of this Agreement, or your failure or
      refusal to carry out any material tasks assigned to you by the Company in
      accordance with the terms hereof, which breach or failure continues for a
      period of more than thirty (30) days after your receipt of written notice
      thereof from the Company, (iv) the commission by you of any act of fraud,
      embezzlement or deliberate disregard of a rule or policy of the Company
      known to you or contained in a policy and procedure manual provided to you
      which results in material loss, damage or injury to the Company, or (v)
      the material breach by you of any of the provisions of the Confidentiality
      and Noncompetition Agreement substantially in the form of Attachment A to
      this letter.

      4. Benefits. You will be entitled as an employee of the Company to receive
such benefits as are generally provided its employees and executives and for
which you are eligible in accordance with Company policy as in effect from time
to time. The Company retains the right to change, add or cease any particular
benefit relating to its employees and executives generally. At this time, the
Company is offering a benefit program, consisting of medical, dental, life and
short/long term disability insurance, as well as a 401(k) retirement plan and
flexible spending plan. You will be eligible for eight paid holidays, four
floating holidays and four weeks paid vacation per year. You will accrue
additional vacation days in accordance with Company policy.

      5. Confidentiality. The Company considers the protection of its
confidential information and proprietary materials to be very important.
Therefore, as a condition of your employment, you and the Company will become
parties to a Confidentiality and Noncompetition Agreement substantially in the
form of Attachment A to this letter (the "Confidentiality Agreement").

                                       2

<PAGE>
      6. General.

         (a)  This letter, together with the Confidentiality Agreement and the
      Stock Option Agreement, will constitute our entire agreement as to your
      employment by the Company and will supersede any prior agreements or
      understandings, whether in writing or oral.

         (b)  This letter shall be subject to and contingent upon the
      satisfactory results of a medical physical. The Company will accept a
      summary of a medical examination by your family doctor within the past
      month.

         (c)  This letter shall be subject to and contingent upon the
      satisfactory review of references and personal background review.

         (d)  This letter and the Company's obligations hereunder shall be
      subject to review and approval by the Company's Board of Directors and
      the Compensation Committee thereof.

         (e)  This letter shall be governed by the law of the State of New
      Jersey.

      You may accept this offer of employment and the terms thereof by signing
the enclosed additional copy of this letter, the Confidentiality Agreement and
the Stock Option Agreement, which execution will evidence your agreement with
the terms set forth herein and therein, and returning all three documents to the
Company.

      This offer of employment will expire on December 18, 2003, unless accepted
by you prior to such date. We look forward to you joining our team, and we
believe that your skills will compliment those of our existing management team,
and that you will make a significant contribution to the Company's growth. We
look forward to your prompt response to this offer letter.

Sincerely,

MEMORY PHARMACEUTICALS CORP.

By:  /s/ Tony Scullion
    ----------------------
Name:  Tony Scullion
Title: Chief Executive Officer

ACCEPTED AND AGREED:

/s/ Dennis Keane
--------------------------
Dennis Keane

Date:   12/16/03
      --------------------

                                       3

<PAGE>
                                  ATTACHMENT A

                  CONFIDENTIALITY AND NONCOMPETITION AGREEMENT

                          MEMORY PHARMACEUTICALS CORP.

                                                               December 16, 2003

Mr. Dennis Keane
50 Constant Avenue
Yonkers, NY  10701

Dear Dennis:

      This letter is to confirm our understanding with respect to (i) your
agreement to protect and preserve information and property which is confidential
and proprietary to Memory Pharmaceuticals Corp. or its parent, subsidiaries or
affiliates, if any (the "Company"), and (ii) your agreement not to compete with
the Company (the terms and conditions agreed to in this letter shall hereinafter
be referred to as the "Agreement"). In consideration of the offer of employment
with the Company, the mutual promises and covenants contained in this Agreement,
and for other good and valuable consideration, the receipt and sufficiency of
which are hereby mutually acknowledged, we have agreed as follows:

      1. Protected Information. You shall at all times, both during and after
the termination of your employment with the Company, by either you or the
Company, with or without cause, maintain in confidence and shall not, without
the prior written consent of the Company, directly or indirectly use, except in
the course of performance of your duties for the Company, directly or indirectly
disclose or give to others any fact, information or document (whether printed,
typed, handwritten, electronic or stored on computer disks, tapes, hard drives
or any other tangible medium) which was disclosed to or developed by you during
the course of performing services for, and/or receiving training from, the
Company, and is not generally available to the public, including but not limited
to, information, facts and documents concerning business plans, research and
development, customers, suppliers, licensors, licensees, partners, investors,
affiliates or others, training methods and materials, financial information,
sales prospects, client lists, methodologies, formulae, designs, schematics,
charts, Inventions (as defined in Section 2), or any other scientific,
technical, trade or business secret or confidential or proprietary information
("Confidential Information") of the Company or of any third party provided to
you during the course of your training and/or employment.

      In the event you are questioned by anyone not employed by the Company or
by an employee of or a consultant to the Company not authorized to receive such
information, in

<PAGE>

regard to any Confidential Information or any other secret or confidential work
of the Company, or concerning any fact or circumstance relating thereto, or in
the event that you become aware of the unauthorized use of Confidential
Information by any party, whether competitive with the Company or not, you will
promptly notify the president of the Company.

      2.    Ownership of ideas, Copyrights and Patents.

            (a) Property of the Company. You agree that all ideas, discoveries,
creations, manuscripts and properties, innovations, improvements, know-how,
Inventions, designs, developments, apparatus, techniques, algorithms, software,
mask works, methods, and formulae (all of the foregoing being hereinafter
referred to as the "Inventions") which may be used in the business of the
Company, whether patentable, copyrightable, protectable as mask works or not,
which you may conceive, reduce to practice or develop alone or in conjunction
with another, or others, and whether at the request or upon the suggestion of
the Company, or otherwise, during the period in which you perform services for
or at the request of the Company (the "Term") and, with respect to Inventions in
Field of Interest (as defined below), for a period of one (1) year thereafter,
shall be the sole and exclusive property of the Company, that you shall promptly
disclose any such Inventions to the Company both during and after the Term, and
that you shall not publish any such Inventions without the prior written consent
of the Company. You hereby assign to the Company all of your rights, titles and
interests in and to all of the foregoing. You further represent and agree that
to the best of your knowledge and belief, none of the Inventions will violate or
infringe upon any right, patent, copyright, trademark or right of privacy, or
constitute libel or slander against or violate any other rights of any person,
firm or corporation, and that you will use your best efforts to prevent any such
violation. You also agree that you will neither disclose to the Company or any
of its employees nor use for their benefit any other person's or company's trade
secret or proprietary information, or information which you have agreed not to
disclose or use.

            (b) Cooperation. At any time during or after the Term, you agree
that you will fully cooperate with the Company, its attorneys and agents in the
preparation and filing of all papers and other documents as may be required to
perfect and protect the Company's rights in and to any of such Inventions,
including, but not limited to, joining in any proceeding to obtain and enforce
letters patent, copyrights, mask work registrations, trademarks or other legal
rights of the United States and of any and all other countries on such
Inventions, provided that the Company will bear the expense of such proceedings,
and that any patent, copyright, mask work registration, trademark or other legal
right so issued to you, personally, shall be assigned by you to the Company
without charge by you.

      3.    Prohibited Competition.

            (a) Certain Acknowledgments and Agreements.

                  (i) We have discussed, and you recognize and acknowledge the
competitive and proprietary aspects of the business of the Company.

                  (ii) You further acknowledge and agree that, during the course
of your performing services for the Company, the Company will furnish, disclose
or make available to

                                       2
<PAGE>

you Confidential Information related to the Company's business and that the
Company may provide you with unique and specialized training. You also
acknowledge that such Confidential Information and such training have been
developed and will be developed by the Company through the expenditure by the
Company of substantial time, effort and money. You acknowledge that such
Confidential Information and training, if used by you to compete with the
Company, will cause irreparable harm to the Company. You also acknowledge that
the Company has a legitimate business interest in protecting its Confidential
Information.

                  (iii) You acknowledge that the Company is engaged in the
research, development or commercialization of agents to affect memory, cognitive
abilities or any related neurological or psychiatric function (the "Field of
Interest") and that any engagement by you, directly or indirectly, in the Field
of Interest will be deemed competitive. You further acknowledge that the
foregoing description is not exclusive and that the Company's products and
services and planned products and services will change from time to time without
notice to you and without formal amendment of this Agreement.

            (b) Covenants Not to Compete. During the Term and for a period of
one year following the expiration or termination of the Term, whether such
termination is voluntary or involuntary, with or without cause, you shall not,
without the prior written consent of the Company:

                  (i) for yourself or on behalf of any other person or entity,
directly or indirectly, either as principal, agent, employee, consultant,
representative or in any other capacity, own, manage, operate or control, or be
connected or employed by, or otherwise associate in any manner with, or engage
in any business which is in the Field of Interest within the United States,
Europe or Japan (the "Restricted Territory"); or

                  (ii) either individually or on behalf of or through any third
party, solicit, divert or appropriate or attempt to solicit, divert or
appropriate, for the purpose or with the effect of competing with the Company in
the Field of Interest or any present or future parent, subsidiary or other
affiliate of the Company which is engaged in a similar business as the Company,
any customers or patrons of the Company, or any prospective customers or patrons
with respect to which the Company has developed or made a sales presentation (or
similar offering of services), located within the Restricted Territory; or

                  (iii) either individually or on behalf of or through any third
party, directly or indirectly, solicit, entice or persuade or attempt to
solicit, entice or persuade any other employees of or consultants to the Company
or any present or future parent, subsidiary or affiliate of the Company, to
leave the services of the Company or any such parent, subsidiary or affiliate
for any reason. You acknowledge that the Company has invested a great deal of
time and money in attracting and retaining its employees and in training its
employees in the Company's particular business. You acknowledge that the Company
has a legitimate interest in protecting this investment.

            (c) Reasonableness of Restrictions. You further recognize and
acknowledge that (i) the types of activities and employment which are prohibited
by Section 3 are narrow and reasonable in relation to the skills which represent
your principal salable asset both to the

                                       3
<PAGE>

Company and to your other prospective employers, and (ii) the geographical scope
of the provisions of Section 3 is reasonable, legitimate and fair to you in
light of the geographic scope of the Company's business, and in light of the
limited restrictions on the type of employment prohibited herein compared to the
types of employment for which you are qualified to earn your livelihood.

      4. Survival of Acknowledgments and Agreements. Your acknowledgments and
agreements set forth in Sections 1, 2 and 3 shall survive the expiration or
termination of this Agreement and the termination of your employment with the
Company for any reason.

      5. Disclosure to Future Employers. You agree that you will provide, and
that the Company may similarly provide in its discretion, a copy of the
covenants contained in Sections 1, 2 and 3 of this Agreement to any business or
enterprise which you may directly, or indirectly, own, manage, operate, finance,
join, control or in which you participate in the ownership, management,
operation, financing, or control, or with which you may be connected as an
officer, director, employee, partner, principal, agent, representative,
consultant or otherwise.

      6. Records. Upon termination of your relationship with the Company, you
shall deliver immediately to the Company any property of the Company which may
be in your possession including products, materials, memoranda, notes, records,
reports, or other documents or photocopies of the same, including without
limitation any of the foregoing recorded on any computer or any machine readable
medium.

      7. No Conflicting Agreements. You have set forth on Exhibit 1 hereto all
computer software and/or Inventions made or conceived by you prior to the date
of this Agreement which you own an interest in and wish to exclude from this
Agreement and have listed on Exhibit 1 and attached copies hereto of any
agreements with other parties which may prevent your full compliance with the
terms stated herein. You hereby represent and warrant that, except as set forth
on Exhibit 1, you have no commitments or obligations inconsistent with this
Agreement and you hereby agree to indemnify and hold the Company harmless
against loss, damage, liability or expense arising from any claim based upon
circumstances alleged to be inconsistent with such representation and warranty.

      8. General.

            (a) Notices. All notices, requests, consents and other
communications hereunder shall be in writing, shall be addressed to the
receiving party's address set forth below or to such other address as a party
may designate by notice hereunder, and shall be either (i) delivered by hand,
(ii) made by telecopy or facsimile transmission, (iii) sent by overnight
courier, or (iv) sent by registered or certified mail, return receipt requested,
postage prepaid.

If to the Company:                 Memory Pharmaceuticals Corp.
                                   100 Philips Parkway
                                   Montvale, New Jersey  07645
                                   Attention:  Chief Financial Officer

                                       4
<PAGE>

With a copy to:                    Sills Cummis Radin Tischman Epstein & Gross
                                   One Riverfront Plaza
                                   Newark, New Jersey  07102
                                   Attn:  Ira A. Rosenberg, Esq.

If to Employee:                    Dennis Keane
                                   50 Constant Avenue
                                   Yonkers, NY  10701

All notices, requests, consents and other communications hereunder shall be
deemed to have been given either (i) if by hand, at the time of the delivery
thereof to the receiving party at the address of such party set forth above,
(ii) if made by telecopy or facsimile transmission, at the time that receipt
thereof has been acknowledged by electronic confirmation or otherwise, (iii) if
sent by overnight courier, on the next, business day following the day such
notice is delivered to the courier service, or (iv) if sent by registered or
certified mail, on the fifth business day following the day such mailing is
made.

            (b) Entire Agreement. This Agreement embodies the entire agreement
and understanding between the parties hereto with respect to the subject matter
hereof and supersedes all prior oral or written agreements and understandings
relating to the subject matter hereof. No statement, representation, warranty,
covenant or agreement of any kind not expressly set forth in this Agreement
shall affect, or be used to interpret, change or restrict, the express terms and
provisions of this Agreement.

            (c) Modifications and Amendments. The terms and provisions of this
Agreement may be modified or amended only by written agreement executed by the
parties hereto.

            (d) Waivers and Consents. The terms and provisions of this Agreement
may be waived, or consent for the departure therefrom granted, only by written
document executed by the party entitled to the benefits of such terms or
provisions. No such waiver or consent shall be deemed to be or shall constitute
a waiver or consent with respect to any other terms or provisions of this
Agreement, whether or not similar. Each such waiver or consent shall be
effective only in the specific instance and for the purpose for which it was
given, and shall not constitute a continuing waiver or consent.

            (e) Assignment. The Company may assign its rights and obligations
hereunder to any person or entity who succeeds to all or substantially all of
the Company's business or that aspect of the Company's business in which you are
principally involved. Your rights and obligations under this Agreement may not
be assigned by you without the prior written consent of the Company.

            (f) Benefit. All statements, representations, warranties, covenants
and agreements in this Agreement shall be binding on the parties hereto and
shall inure to the benefit of the respective successors and permitted assigns of
each party hereto. Nothing in this Agreement shall be construed to create any
rights or obligations except among the parties hereto, and no person or entity
shall be regarded as a third-party beneficiary of this Agreement.

                                       5
<PAGE>

            (g) Governing Law. This Agreement and the rights and obligations of
the parties hereunder shall be construed in accordance with and governed by the
law of the State of New Jersey, without giving effect to the conflict of law
principles thereof.

            (h) Jurisdiction and Service of Process. Any legal action or
proceeding with respect to this Agreement shall be brought in the courts of the
State of New Jersey or of the United States District Court for the District of
New Jersey. By execution and delivery of this Agreement, each of the parties
hereto accepts for itself and in respect of its property, generally and
unconditionally, the jurisdiction of the aforesaid courts. Each of the parties
hereto irrevocably consents to the service of process of any of the
aforementioned courts in any such action or proceeding by the mailing of copies
thereof by certified mail, postage prepaid, to the party at its address set
forth in Section 8(a) hereof.

            (i) Severability. The parties intend this Agreement to be enforced
as written. However, (i) if any portion or provision of this Agreement shall to
any extent be declared illegal or unenforceable by a duly authorized court
having jurisdiction, then the remainder of this Agreement, or the application of
such portion or provision in circumstances other than those as to which it is so
declared illegal or unenforceable, shall not be affected thereby, and each
portion and provision of this Agreement shall be valid and enforceable to the
fullest extent permitted by law; and (ii) if any provision, or part thereof, is
held to be unenforceable because of the duration of such provision or the
geographic area covered thereby, the Company and you agree that the court making
such determination shall have the power to reduce the duration and/or geographic
area of such provision, and/or to delete specific words and phrases
("blue-pencilling"), and in its reduced or blue-pencilled form such provision
shall then be enforceable and shall be enforced.

            (j) Interpretation. The parties hereto acknowledge and agree that
the terms and provisions of this Agreement, shall be construed fairly as to all
parties hereto and not in favor of or against a party, regardless of which party
was generally responsible for the preparation of this Agreement.

            (k) Headings and Captions. The headings and captions of the various
subdivisions of this Agreement are for convenience of reference only and shall
in no way modify, or affect the meaning or construction of any of the terms or
provisions hereof.

            (l) Injunctive Relief. You hereby expressly acknowledge that any
breach or threatened breach of any of the terms and/or conditions set forth in
Sections 1, 2 or 3 of this Agreement will result in substantial, continuing and
irreparable injury to the Company. Therefore, you hereby agree that, in addition
to any other remedy that may be available to the Company, the Company shall be
entitled to injunctive or other equitable relief by a court of appropriate
jurisdiction, without posting a bond, in the event of any breach or threatened
breach of the terms of Sections 1, 2 or 3 of this Agreement.

            (m) No Waiver of Rights, Powers and Remedies. No failure or delay by
a party hereto in exercising any right, power or remedy under this Agreement,
and no course of dealing between the parties hereto, shall operate as a waiver
of any such right, power or remedy of the party. No single or partial exercise
of any right, power or remedy under this Agreement by a party hereto, nor any
abandonment or discontinuance of steps to enforce any such right,

                                       6
<PAGE>

power or remedy, shall preclude such party from any other or further exercise
thereof or the exercise of any other right, power or remedy hereunder. The
election of any remedy by a party hereto shall not constitute a waiver of the
right of such party to pursue other available remedies. No notice to or demand
on a party not expressly required under this Agreement shall entitle the party
receiving such notice or demand to any other or further notice or demand in
similar or other circumstances or constitute a waiver of the rights of the party
giving such notice or demand to any other or further action in any circumstances
without such notice or demand.

            (n) Expenses. Should any party breach this Agreement, in addition to
all other remedies available at law or in equity, such breaching party shall pay
all of any other party's costs and expenses resulting therefrom and/or incurred
in enforcing this Agreement, including legal fees and expenses.

            (o) Counterparts. This Agreement may be executed in one or more
counterparts, and by different parties hereto on separate counterparts, each of
which shall be deemed an original, but all of which together shall constitute
one and the same instrument.

      If the foregoing accurately sets forth our agreement, please so indicate
by signing and returning to us the enclosed copy of this letter.

                                          Very truly yours,

                                          MEMORY PHARMACEUTICALS CORP.

                                          BY:    /S/ TONY SCULLION
                                                 -------------------------------
                                          Name:  Tony Scullion
                                          Title: Chief Executive Officer

     Accepted and Approved

  /s/ Dennis Keane
------------------------------------
Dennis Keane
Dated:  December 16, 2003

                                       7<PAGE>

                                                                   Exhibit 10.16

                        TRAVELERS PROPERTY CASUALTY CORP
                                COMPENSATION PLAN
                     FOR NON-EMPLOYEE DIRECTORS (THE "PLAN")

            Section 1. ELIGIBILITY. Each member of the Board of Directors of the
Travelers Property Casualty Corp. (the "Company") or one of its subsidiaries, if
so designated by the Board of Directors, who is not an employee of the Company
or any of its subsidiaries (an "Eligible Director") is eligible to participate
in the Plan.

            Section 2. ADMINISTRATION. The Plan shall be administered, construed
and interpreted by the Board of Directors of the Company. Pursuant to such
authorization, the Board of Directors shall have the responsibility for carrying
out the terms of the Plan, including but not limited to the determination of the
amount and form of payment of the annual retainer and any additional fees to be
paid to all Eligible Directors (the "Annual Fixed Director Compensation"). To
the extent permitted under the securities laws applicable to compensation plans
including, without limitation, the requirements of Section 16(b) of the
Securities Exchange Act of 1934, as amended (the "Exchange Act") or under the
Internal Revenue Code of 1986, as amended (the "Code"), the Personnel,
Compensation and Directors Committee of the Board of Directors, or a
subcommittee of the Personnel, Compensation and Directors Committee, may
exercise the discretion granted to the Board under the Plan, provided that the
composition of such Committee or subcommittee shall satisfy the requirements of
Rule 16b-3 under the Exchange Act, or any successor rule or regulation. The
Board of Directors may also designate a plan administrator to manage the record
keeping and other routine administrative duties under the Plan.

            Section 3. STOCK OPTIONS. In addition to Annual Fixed Director
Compensation, the Board of Directors may make an annual grant to Eligible
Directors of options ("Annual Stock Option Grant") to purchase common stock, par
value $.01 of the Company ("Common Stock"). The Annual Stock Option Grant shall
be made under, and pursuant to the terms and conditions of, the Travelers
Property Casualty Corp. 2002 Stock Incentive Plan or any successor plan (the
"Stock Incentive Plan").

            Section 4. ANNUAL FIXED DIRECTOR COMPENSATION. Payment of Annual
Fixed Director Compensation shall be made quarterly, on the first business day
following the end of the quarter for which the compensation is payable, to each
Eligible Director who served as a director during at least one-half of such
quarter and who was a director on the last day of such quarter.

            Each Eligible Director may elect to receive up to fifty percent
(50%) of each quarterly payment of Annual Fixed Director Compensation in cash.
The balance of each quarterly payment shall be paid in shares of Common Stock or
in the form of stock options, as each Eligible Director elects. Payment in stock
options shall be under the same plan and pursuant to the same terms and
conditions as the Annual Stock Option Grant. If an Eligible

                                       1
<PAGE>
Director does not elect to receive a percentage of his or her Annual Fixed
Director Compensation in cash or stock options, such compensation shall be paid
entirely in Common Stock.

            The number of shares of Common Stock to be transferred to the
Eligible Director in respect of each quarterly installment of Annual Fixed
Director Compensation shall be determined in the manner set forth in paragraph
6(a), and such shares shall not be transferred or sold by such Eligible Director
for a period of six months following the date of grant.

            Section 5. ELECTION TO DEFER.

                  (A) TIME OF ELECTION. As soon as practicable prior to the
beginning of a calendar year, an Eligible Director may elect to defer receipt of
the Common Stock component of Annual Fixed Director Compensation by directing
that such Common Stock which otherwise would have been payable in accordance
with paragraph 3 above during such calendar year and succeeding calendar years
shall be credited to a deferred compensation account (the "Director's Account").
Under a valid election, such deferred compensation shall be payable in
accordance with paragraph 7(a) below. Any person who shall become an Eligible
Director during any calendar year, and who was not an Eligible Director of the
Company (or its subsidiaries) prior to the beginning of such calendar year, may
elect, within thirty (30) days after his or her term begins, to defer payment of
the Common Stock component of his or her Annual Fixed Director Compensation
earned during the remainder of such calendar year and for succeeding calendar
years. The cash component of Annual Fixed Director Compensation may not be
deferred.

                  (B) FORM AND DURATION OF ELECTION. An election to defer the
Common Stock component of Annual Fixed Director Compensation shall be made by
written notice executed by the Eligible Director and filed with the Secretary of
the Company. Such election shall continue until the Eligible Director terminates
such election by subsequent written notice filed with the Secretary of the
Company. Any such election to terminate deferral shall become effective for the
calendar quarter following receipt of the election form by the Company and shall
only be effective with respect to the Common Stock component of Annual Fixed
Director Compensation payable for services rendered as an Eligible Director
thereafter. Amounts credited to the Director's Account prior to the effective
date of termination shall not be affected by such termination and shall be
distributed only in accordance with the terms of the Plan.

                  (C) CHANGE OF ELECTION. An Eligible Director who has
terminated his or her election to defer the Common Stock component of Annual
Fixed Director Compensation hereunder may thereafter make another election in
accordance with paragraph 5(a) to defer such compensation for the calendar year
subsequent to the filing of such election and succeeding calendar years.

            Section 6. THE DIRECTOR'S ACCOUNT. Shares of Common Stock that an
Eligible Director has elected to defer under the Plan shall be credited to the
Director's Account as follows:

                  (a) As of each date that a quarterly installment of the Annual
Fixed Director Compensation would otherwise be payable, there shall be credited
to the Director's Account the number of full shares of the Company's Common
Stock obtained by multiplying the

                                       2
<PAGE>
percentage such Eligible Director has elected to receive in shares of Common
Stock by the total amount of Annual Fixed Director Compensation allocable to
such calendar quarter, and then by dividing the result by the average of the
closing price of the Company's Common Stock on the New York Stock Exchange Inc.
on the last ten (10) trading days of the calendar quarter for which such Common
Stock would otherwise be payable. If the applicable percentage of Annual Fixed
Director Compensation for the calendar quarter is not evenly divisible by such
average closing price of the Company's Common Stock, the balance shall be
credited to the Director's Account in cash.

                  (b) At the end of each calendar quarter, there shall be
credited to the Director's Account an amount equal to the cash dividends that
would have been paid on the number of shares of Common Stock credited to the
Director's Account as of the dividend record date, if any, occurring during such
calendar quarter as if such shares had been shares of issued and outstanding
Common Stock on such record date, and such amount shall be treated as reinvested
in additional shares of Common Stock on the dividend payment date.

                  (c) Cash amounts credited to the Director's Account pursuant
to subparagraphs (a) and (b) above shall accrue interest commencing from the
date the cash amounts are credited to the Director's Account at a rate per annum
to be determined from time to time by the Company. Amounts credited to the
Director's Account shall continue to accrue interest until distributed in
accordance with the Plan. An Eligible Director may be given the opportunity make
a written election to treat the existing cash balance and interest accrued
thereon as invested in additional shares of Common Stock. The timing of the
effectiveness of such election shall be subject to the Company's discretion.

                  (d) An Eligible Director shall not have any interest in the
cash or Common Stock in his or her Director's Account until such cash or Common
Stock is distributed in accordance with the Plan.

            Section 7. DISTRIBUTION FROM ACCOUNTS.

                  (A) FORM OF ELECTION. At the time an Eligible Director makes
an election to defer receipt of Annual Fixed Director Compensation pursuant to
paragraphs 5(a) or 5(c), such Director shall also file with the Secretary of the
Company a written election with respect to the distribution of the aggregate
amount of cash and shares credited to the Director's Account pursuant to such
election. An Eligible Director may elect to receive such amount in one lump-sum
payment or in a number of approximately equal annual installments (provided the
payout period does not exceed 15 years). The lump-sum payment or the first
installment shall be paid as of (i) the first business day of any calendar year
subsequent to the date the Annual Fixed Director Compensation would otherwise be
payable, as specified by the Director, (ii) the first business day of the
calendar quarter immediately following the cessation of the Eligible Director's
service as a director of the Company or (iii) the earlier of (i) or (ii), as the
Eligible Director may elect. Subsequent installments shall be paid as of the
first business day of each succeeding annual installment period until the entire
amount credited to the Director's Account shall have been paid. A cash payment
will be made with the final installment for any fraction of a share of Common
Stock credited to the Director's Account.

                                       3
<PAGE>
                  (B) ADJUSTMENT OF METHOD OF DISTRIBUTION. An Eligible Director
participating in the Plan may, prior to the beginning of any calendar year, file
another written election with the Secretary of the Company electing to change
the date and/or method of distribution of the aggregate amount of cash and
shares of Common Stock to be credited to the Director's Account for services
rendered as a director commencing with such calendar year. Amounts credited to
the Director's Account prior to the effective date of such change (the "Prior
Amounts") shall not be affected by such change and shall be distributed only in
accordance with the election then in effect with respect to the Prior Amounts
except as specified in this paragraph. An Eligible Director may elect to defer
the date on which Prior Amounts are to be paid, and/or extend the payout period
if a written election to effect such change is filed with the Secretary of the
Company at least one (1) year before such change is to take effect. An Eligible
Director may also elect to accelerate the date on which the Prior Amounts are to
be paid and/or shorten the payout period if a written election to effect such
change is filed with the Secretary of the Company at least one (1) year before
such change is to effect. Notwithstanding the foregoing, in the event an
Eligible Director suffers a severe financial hardship outside the control of
such Director, as determined by the Company, the Eligible Director may elect to
advance or defer the date of distribution of his or her Director's Account or
change the method of distribution thereof.

                  (C) CHANGE OF CONTROL. Notwithstanding anything to the
contrary contained herein, upon a "Change of Control" (as defined in the Stock
Incentive Plan), the full number of shares of Common Stock and cash in each
Director's Account shall be immediately funded and be distributable on the later
of the date six months and one day following the "Change of Control" or the
distribution date(s) previously elected by an Eligible Director; provided
however, that the merger of the Company as set forth in the Agreement and Plan
of Merger dated as of November 16, 2003, among The St. Paul Companies, Inc.,
Travelers Property Casualty Corp. and Adams Acquisition Corp., shall not
constitute a "Change of Control" for purposes of this Plan.

            Section 8. DISTRIBUTION ON DEATH. If an Eligible Director should die
before all amounts credited to the Director's Account shall have been paid in
accordance with the election referred to in paragraph 6, the balance in such
Director's Account as of the date of such Director's death shall be paid
promptly following such Director's death, in accordance with the method of
payment elected by the Eligible Director, to the beneficiary designated in
writing by such Director. Such balance shall be paid to the estate of the
Eligible Director if (a) no such designation has been made or (b) the designated
beneficiary shall have predeceased the Director and no further beneficiary
designation has been made.

            Section 9. MISCELLANEOUS.

                  (a) The right of an Eligible Director to receive any amount in
the Director's Account shall not be transferable or assignable by such Director,
except by will or by the laws of descent and distribution, and no part of such
amount shall be subject to attachment or other legal process.

                                       4
<PAGE>
                  (b) Except as otherwise set forth herein, the Company shall
not be required to reserve or otherwise set aside funds or shares of Common
Stock for the payment of its obligations hereunder. The Company shall make
available as and when required a sufficient number of shares of Common Stock to
meet the requirements arising under the Plan.

                  (c) The establishment and maintenance of, or allocation and
credits to, the Director's Account shall not vest in the Eligible Director or
his beneficiary any right, title or interest in and to any specific assets of
the Company. An Eligible Director shall not have any dividend or voting rights
or any other rights of a stockholder (except as expressly set forth in paragraph
6(b) with respect to dividends and as provided in subparagraph (f) below) until
the shares of Common Stock credited to a Director's Account are distributed. The
rights of an Eligible Director to receive payments under this Plan shall be no
greater than the right of an unsecured general creditor of the Company.

                  (d) The Plan shall continue in effect until terminated by the
Board of Directors. The Board of Directors may at any time amend or terminate
the Plan; provided, however, that (i) no amendment or termination shall impair
the rights of an Eligible Director with respect to amounts then credited to the
Director's Account; (ii) the provisions of the Plan relating to eligibility, the
amount and price of securities to be awarded, the timing of and the amount of
Annual Fixed Director Compensation awards and Annual Stock Option Grant shall
not be amended more than once every six months, other than to comport with
changes in the Internal Revenue Code of 1986, as amended, the Employee
Retirement Income Security Act of 1974, as amended, or the rules thereunder; and
(iii) no amendment shall become effective without approval of the stockholders
of the Company if such stockholder approval is required to enable the Plan to
satisfy applicable state or Federal statutory or regulatory requirements.

                  (e) Each Eligible Director participating in the Plan will
receive an annual statement indicating the amount of cash and number of shares
of Common Stock credited to the Director's Account, as well as the number of
outstanding stock options, as of the end of the preceding calendar year.

                  (f) If adjustments are made to outstanding shares of Common
Stock as a result of stock dividends, stock splits, recapitalizations, mergers,
consolidations and similar transactions, an appropriate adjustment shall be made
in the number of shares of Common Stock credited to the Director's Account.

                  (g) Shares of Common Stock that may be granted under the Plan
shall be subject to adjustment upon the occurrence of adjustments to the
outstanding Common Stock described in paragraph 9(f) hereof.

                  (h) The validity, construction, interpretation, administration
and effect of the Plan and of its rules and regulations, and rights relating to
the Plan, shall be determined solely in accordance with the laws of the State of
Connecticut, without regard to the conflicts of laws provisions thereof.

                                       5
<PAGE>
                  (i) All claims and disputes between an Eligible Director and
the Company arising out of the Plan shall be submitted to arbitration in
accordance with the then current arbitration policy of the Company. Notice of
demand for arbitration shall be given in writing to the other party and shall be
made within a reasonable time after the claim or dispute has arisen. The award
rendered by the arbitrator shall be final, and judgment may be entered upon it
in accordance with applicable law in any court having jurisdiction thereof. The
provisions of this Section 9(i) shall be specifically enforceable under
applicable law in any court having jurisdiction thereof.

                  (j) If any term or provision of this Plan or the application
thereof to any person or circumstances shall, to any extent, be invalid or
unenforceable, then the remainder of the Plan, or the application of such term
or provision to persons or circumstances other than those as to which it is held
invalid or unenforceable, shall not be affected thereby, and each term and
provision hereof shall be valid and be enforced to the fullest extent permitted
by applicable law.

                                       6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00061-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00061-of-00352.parquet"}]]